Neoadjuvant Treatment in Breast Cancer; Relationship to HER2 status including HER2 Copy Number using Brightfield Dual in situ Hybridization

被引：0
|
作者：
Neville, Grace [1 ]
O'Connell, Fionnuala [1 ]
Bennett, Michael [1 ]
Feeley, Linda
O'Reilly, Seamus [1 ]
Browne, Tara Jane [1 ]
机构：
[1] Cork Univ Hosp, Cork, Ireland
来源：
MODERN PATHOLOGY | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
268
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant Treatment in Breast Cancer; Relationship to HER2 status including HER2 Copy Number using Brightfield Dual in situ Hybridization
    Neville, Grace
    O'Connell, Fionnuala
    Bennett, Michael
    Feeley, Linda
    O'Reilly, Seamus
    Browne, Tara Jane
    LABORATORY INVESTIGATION, 2018, 98 : 95 - 95
  • [2] The Relationship of HER2 Copy Number Evaluated by Brightfield Dual In Situ Hybridisation DNA Assay and Pathologic Response to Neoadjuvant Treatment in HER2 Positive Breast Cancer
    Neville, G.
    Feeley, L.
    Bennett, M. W.
    O'Reilly, S.
    Corrigan, M.
    O'Connell, F.
    Browne, T. J.
    JOURNAL OF PATHOLOGY, 2017, 243 : S22 - S22
  • [3] Dual-Color In Situ Hybridization (Dual ISH) for Evaluation of HER2/Neu (HER2) Amplification in Breast Cancer
    Astvatsaturyan, K.
    Bose, S.
    MODERN PATHOLOGY, 2013, 26 : 28A - 28A
  • [4] Dual-Color In Situ Hybridization (Dual ISH) for Evaluation of HER2/Neu (HER2) Amplification in Breast Cancer
    Astvatsaturyan, K.
    Bose, S.
    LABORATORY INVESTIGATION, 2013, 93 : 28A - 28A
  • [5] Assessment of HER2 status in invasive breast cancer with increased centromere 17 copy number by fluorescence in situ hybridization
    Jang, Min Hye
    Kim, Eun Joo
    Kim, Hyun Jeong
    Park, So Yeon
    CANCER RESEARCH, 2015, 75
  • [6] Changes in HER2 status after neoadjuvant treatment of breast cancer
    Skalova, H.
    Dundr, P.
    Povysil, C.
    Pribylova, O.
    Petruzelka, L. B.
    Tvrdik, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Predictive Value of HER2 Fluorescence In Situ Hybridization (FISH) Result in HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Suo, Aili
    Zhang, Chao
    Shi, Quiying
    Wei, Zhimin
    Li, Zaibo
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [9] Predictive Value of HER2 Fluorescence In Situ Hybridization (FISH) Result in HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Suo, Aili
    Zhang, Chao
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [10] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
12345